Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03360890 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors
A Phase 2 study of Thyroid Cancer and Salivary Gland Cancer, sponsored by University of Chicago.
- Active
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT03360890 is a Phase 2 study of Thyroid Cancer and Salivary Gland Cancer that is active but no longer recruiting, run by University of Chicago. The registered enrollment target is 46 participants, below the 281-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03360890, a Phase 2 study of Thyroid Cancer and Salivary Gland Cancer, is active but no longer recruiting, sponsored by University of Chicago.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase II, 2-cohort, single arm trial treated with the combination of the following two agents: 1. Pembrolizumab (MK3475) 200mg, every three weeks, iv 2. Docetaxel 75mg/m2, every three weeks, iv
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Docetaxel
Study Locations (1)
Illinois
- University of Chicago Comprehensive Cancer Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2018-03-26 |
| Est. Completion | 2032-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03360890
The ClinicalTrials.gov registry entry for NCT03360890 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 281-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (84% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Thyroid Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03360890 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT03360890 about?
NCT03360890 is a clinical study titled "Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors". Phase II, 2-cohort, single arm trial treated with the combination of the following two agents: 1. Pembrolizumab (MK3475) 200mg, every three weeks, iv 2. Docetaxel 75mg/m2, every three weeks, iv
What is the current status of trial NCT03360890?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2018-03-26. Estimated completion is 2032-09.
What conditions does trial NCT03360890 study?
This clinical trial studies the following conditions: Thyroid Cancer, Salivary Gland Cancer.
What interventions are being tested in trial NCT03360890?
The interventions under investigation include: Pembrolizumab (DRUG), Docetaxel (DRUG).
Who is sponsoring clinical trial NCT03360890?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03360890 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
RECRUITING · Phase 2
-
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
RECRUITING · Phase 2
-
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
RECRUITING · Phase 2
-
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
RECRUITING · Phase 2
-
Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer
RECRUITING · Phase 2
-
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.